tradingkey.logo
tradingkey.logo
Search

Nektar Therapeutics

NKTR
Add to Watchlist
68.630USD
+0.270+0.40%
Market hours 09/18, 13:12ET
2.34BMarket Cap
LossP/E TTM

NKTR Financials

See Nektar Therapeutics's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
2.34B
Dividend TTM
0.00
P/E TTM
-8.66
EPS TTM
-7.92
Revenue
55.23M
Net Profit
-118.96M
ROE
-53.60%
ROA
-31.01%

Nektar Therapeutics Earnings Date

Latest Release
Aug 13, 2026
EPS / Forecast
-1.23/-1.98
Revenue / Forecast
10.13M/10.42M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
58.38%-1.23
49.83%-1.82
-441.76%-1.77
29.42%-1.87
21.50%-2.95
-27.66%-3.62
115.71%0.52
26.43%-2.66
6.97%-3.76
73.95%-2.83
30.54%-3.30
---3.61
---4.04
---10.88
---4.76
---24.78
----
----
----
----
Revenue
-9.34%10.13M
3.83%10.86M
-25.25%21.81M
-51.13%11.79M
-52.42%11.18M
-51.66%10.46M
22.15%29.18M
-0.08%24.12M
14.59%23.49M
0.21%21.64M
8.45%23.89M
2.20%24.14M
-5.03%20.50M
-13.00%21.59M
-11.94%22.02M
-5.20%23.63M
-23.81%21.59M
4.97%24.82M
6.59%25.01M
-17.02%24.92M
Net Profit
2.33%-40.62M
11.75%-44.90M
-596.89%-36.08M
4.14%-35.52M
20.57%-41.59M
-38.26%-50.88M
117.26%7.26M
19.15%-37.06M
-2.43%-52.36M
73.14%-36.80M
29.50%-42.08M
22.37%-45.84M
67.86%-51.12M
-51.58%-137.02M
59.02%-59.69M
54.47%-59.05M
-26.73%-159.07M
26.49%-90.39M
-24.27%-145.65M
-19.45%-129.71M
Net Margin
-7.73%-400.97%
15.01%-413.44%
-764.77%-165.45%
-96.14%-301.29%
-66.96%-372.20%
-186.02%-486.44%
114.13%24.89%
19.09%-153.61%
10.61%-222.93%
73.20%-170.07%
35.00%-176.17%
---189.85%
---249.39%
---634.52%
---271.03%
---440.53%
----
----
----
----
Gross Margin
0.00%100.00%
0.00%100.00%
37.63%100.00%
22.53%100.00%
70.84%100.00%
65.12%100.00%
4.53%72.66%
68.23%81.62%
-11.15%58.53%
-10.02%60.56%
-3.05%69.51%
--48.51%
--65.88%
--67.31%
--71.70%
--78.01%
----
----
----
----
Debt to assets ratio
--5.24%
--7.90%
--22.52%
--24.94%
----
----
----
----
----
----
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
----
----
----
----
----
Revenue
-9.34%10.13M
3.83%10.86M
-25.25%21.81M
-51.13%11.79M
-52.42%11.18M
-51.66%10.46M
22.15%29.18M
-0.08%24.12M
14.59%23.49M
0.21%21.64M
8.45%23.89M
2.20%24.14M
-5.03%20.50M
-13.00%21.59M
-11.94%22.02M
-5.20%23.63M
-23.81%21.59M
4.97%24.82M
6.59%25.01M
-17.02%24.92M
Operating profit
-16.71%-41.76M
13.77%-38.26M
22.66%-19.09M
8.07%-31.53M
1.92%-35.78M
-28.78%-44.37M
19.50%-24.68M
-2.37%-34.30M
-7.17%-36.48M
6.93%-34.45M
25.02%-30.66M
10.59%-33.50M
27.24%-34.05M
67.84%-37.02M
63.79%-40.89M
67.01%-37.47M
57.54%-46.79M
-5.20%-115.08M
-1.98%-112.91M
-10.23%-113.60M
Net Profit
2.33%-40.62M
11.75%-44.90M
-596.89%-36.08M
4.14%-35.52M
20.57%-41.59M
-38.26%-50.88M
117.26%7.26M
19.15%-37.06M
-2.43%-52.36M
73.14%-36.80M
29.50%-42.08M
22.37%-45.84M
67.86%-51.12M
-51.58%-137.02M
59.02%-59.69M
54.47%-59.05M
-26.73%-159.07M
26.49%-90.39M
-24.27%-145.65M
-19.45%-129.71M
Current assets
296.32%739.40M
156.20%589.04M
1.90%266.27M
-1.79%281.36M
-36.80%186.57M
-28.12%229.91M
-20.99%261.29M
-28.20%286.48M
-33.07%295.19M
-34.87%319.84M
-39.43%330.70M
-33.44%399.02M
-33.73%441.06M
-33.05%491.07M
-31.37%545.97M
-39.21%599.48M
-36.98%665.54M
-33.26%733.46M
-30.09%795.58M
-5.53%986.13M
Total current liabilities
-0.57%70.98M
-18.64%57.71M
-12.81%53.54M
-1.84%66.34M
24.54%71.39M
35.35%70.93M
19.76%61.40M
29.69%67.58M
13.08%57.33M
-12.48%52.41M
-24.83%51.27M
-37.95%52.11M
-51.71%50.69M
-43.12%59.88M
-19.95%68.20M
-39.99%83.99M
-19.87%104.98M
-14.84%105.28M
-26.41%85.20M
10.65%139.97M
Total assets
427.69%1.10B
197.87%763.27M
-7.72%280.41M
-2.15%301.35M
-39.55%207.53M
-35.29%256.24M
-23.66%303.85M
-30.36%307.97M
-30.54%343.33M
-29.50%396.01M
-43.99%398.03M
-43.38%442.24M
-42.66%494.28M
-45.15%561.74M
-36.39%710.60M
-38.85%781.01M
-37.14%861.99M
-29.69%1.02B
-27.40%1.12B
-15.34%1.28B
Total liabilities
-17.15%192.01M
-22.86%187.06M
-21.61%190.57M
-16.53%216.26M
-12.10%231.75M
-9.95%242.50M
-8.96%243.11M
-8.41%259.08M
-11.33%263.65M
-16.07%269.31M
-22.36%267.05M
-23.29%282.88M
-26.27%297.32M
-22.91%320.88M
-21.41%343.96M
-22.48%368.78M
-13.53%403.25M
-9.92%416.23M
-5.16%437.68M
40.87%475.70M
Total equity
3830.21%903.12M
4094.32%576.22M
47.90%89.83M
74.06%85.09M
-130.38%-24.21M
-89.16%13.74M
-53.63%60.74M
-69.33%48.88M
-59.54%79.69M
-47.40%126.70M
-64.27%130.99M
-61.34%159.37M
-57.06%196.96M
-60.38%240.87M
-46.04%366.64M
-48.57%412.22M
-49.31%458.73M
-38.88%607.89M
-36.92%679.51M
-31.55%801.54M
Net operating income
-65.66%-75.77M
9.69%-44.30M
-40.64%-64.96M
-10.99%-48.76M
-21.31%-45.74M
-2.43%-49.05M
1.83%-46.19M
-4.30%-43.93M
26.82%-37.70M
7.76%-47.89M
18.47%-47.05M
49.18%-42.12M
31.30%-51.52M
41.29%-51.91M
61.92%-57.70M
18.04%-82.89M
9.54%-74.99M
-14.71%-88.42M
-53.64%-151.54M
-92.00%-101.14M
Net investment
-904.41%-399.11M
-902.92%-350.79M
-99.38%372.00K
-305.73%-94.87M
192.16%49.62M
126.86%43.69M
246.40%60.21M
-18.25%46.12M
-32.53%16.98M
-52.56%19.26M
-56.56%17.38M
-49.36%56.41M
-70.09%25.17M
-68.84%40.60M
-66.71%40.01M
13521.08%111.39M
15.35%84.15M
1145.73%130.28M
29.61%120.20M
-101.71%-830.00K
Net financing
172681.52%364.57M
7564885.71%529.55M
46491.57%38.67M
1089723.08%141.68M
1010.53%211.00K
-99.98%7.00K
591.67%83.00K
--13.00K
5.56%19.00K
--42.00M
-88.35%12.00K
--0.00
-96.15%18.00K
-100.00%0.00
-95.96%103.00K
-100.00%0.00
-96.16%467.00K
-94.75%938.00K
-98.29%2.55M
139.26%3.66M

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its total revenue reached 55.23M, with a year-on-year change of 98.43M.

What are the current assets of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its current assets were 266.27M, with a year-on-year change of 1.90.

What are the total assets of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its total assets of Nektar Therapeutics were 280.41M, with a year-on-year change of -7.72.

What are the total liabilities of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its total liabilities of Nektar Therapeutics were 190.57M, with a year-on-year change of -21.61.

What is the total equity of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its total equity of Nektar Therapeutics was 89.83M, with a year-on-year change of 47.90.

What is the net operating income of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its net operating income of Nektar Therapeutics was -130.77M, with a year-on-year change of -0.66.

What is the net investment of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its net investment of Nektar Therapeutics was -1.20M, with a year-on-year change of -100.84.

What is the net financing of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its net financing of Nektar Therapeutics was 180.57M, with a year-on-year change of 328.71.

What is the Earnings Per Share (EPS) of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its Earnings Per Share (EPS) was -9.73, with a year-on-year change of -12.09.

What is the net income of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its net income was -164.08M, with a year-on-year change of -37.92.

What is the net margin of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its net profit margin was -297.07, with a year-on-year change of -145.79.

What is the gross margin of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its gross margin was 100.00, with a year-on-year change of 45.30.

What is the debt-to-asset ratio of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its debt-to-asset ratio was 22.52, with a year-on-year change of -25.43.

What is the Return on Equity (ROE) of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its Return on Equity (ROE) was -217.94, with a year-on-year change of -75.62.

What is the Return on Assets (ROA) of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its Return on Assets (ROA) was -56.17, with a year-on-year change of -65.69.

What is the operating profit of Nektar Therapeutics?

According to Nektar Therapeutics's FY2025 earnings report, its operating profit was -130.77M, with a year-on-year change of -0.66.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.